Literature DB >> 23684620

Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients.

Ju Han1, Rui Tian, Bicheng Yong, Canqiao Luo, Pingxian Tan, Jingnan Shen, Tingsheng Peng.   

Abstract

Dysregulation of the receptor tyrosine kinase Axl and its ligand Gas6 has been shown to promote multiple tumorigenic processes, as well as to correlate with worse prognosis in many different tumor types. However, studies of Axl expression and function in osteosarcoma have rarely been reported. In this study, we report that activated Axl is highly expressed in osteosarcoma cells, and this expression is significantly correlated with the recurrence and lung metastasis of osteosarcoma patients. High expression of activated Axl was an independent predictor for worse prognosis in osteosarcoma. Additionally, we confirmed a strong positive correlation between P-Axl and MMP-9 expression in those osteosarcoma patients. In osteosarcoma cell lines MG63 and U2OS, 200 ng/ml rhGas6 could cause obvious increase of P-Axl expression within 30 min, consistent with the expression of P-AKT. In both of the cell lines, Axl activated by rhGas6 could protect the tumor cells from apoptosis caused by serum starvation, and promote tumor cells' migration and invasion in vitro. Together with previous data, these studies suggest that activated Axl participate in the progression of osteosarcoma by resisting tumor cells apoptosis and promoting their migration and invasion, which may be linked to the expression of MMP-9. In the mechanism, AKT signaling pathway may contribute to the function of P-Axl in osteosarcoma rather than ERK pathway.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23684620     DOI: 10.1016/j.bbrc.2013.05.019

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  56 in total

1.  First Axl inhibitor enters clinical trials.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2013-09       Impact factor: 54.908

2.  Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation.

Authors:  Cristina Bárcena; Milica Stefanovic; Anna Tutusaus; Leonel Joannas; Anghara Menéndez; Carmen García-Ruiz; Pau Sancho-Bru; Montserrat Marí; Joan Caballeria; Carla V Rothlin; José C Fernández-Checa; Pablo García de Frutos; Albert Morales
Journal:  J Hepatol       Date:  2015-04-20       Impact factor: 25.083

3.  miR-199a-3p negatively regulates the progression of osteosarcoma through targeting AXL.

Authors:  Rui Tian; Xianbiao Xie; Ju Han; Canqiao Luo; Bicheng Yong; Huizhi Peng; Jingnan Shen; Tingsheng Peng
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

Review 4.  TYRO3: A potential therapeutic target in cancer.

Authors:  Pei-Ling Hsu; Jonathan Jou; Shaw-Jenq Tsai
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-02

5.  Gas6 expression is reduced in advanced breast cancers.

Authors:  Ayman M Ibrahim; Zane Gray; Angelica M Gomes; Leann Myers; Fariba Behbod; Heather L Machado
Journal:  NPJ Precis Oncol       Date:  2020-04-24

Review 6.  Vitamin K effects in human health: new insights beyond bone and cardiovascular health.

Authors:  Maria Fusaro; Maurizio Gallieni; Camillo Porta; Thomas L Nickolas; Pascale Khairallah
Journal:  J Nephrol       Date:  2019-12-19       Impact factor: 3.902

7.  MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.

Authors:  Nellie K McDaniel; Christopher T Cummings; Mari Iida; Justus Hülse; Hannah E Pearson; Eleana Vasileiadi; Rebecca E Parker; Rachel A Orbuch; Olivia J Ondracek; Noah B Welke; Grace H Kang; Kurtis D Davies; Xiaodong Wang; Stephen V Frye; H Shelton Earp; Paul M Harari; Randall J Kimple; Deborah DeRyckere; Douglas K Graham; Deric L Wheeler
Journal:  Mol Cancer Ther       Date:  2018-08-09       Impact factor: 6.261

8.  Icaritin suppresses the proliferation of human osteosarcoma cells in vitro by increasing apoptosis and decreasing MMP expression.

Authors:  Xiao-fang Wang; Jun Wang
Journal:  Acta Pharmacol Sin       Date:  2014-03-10       Impact factor: 6.150

9.  Function of Axl receptor tyrosine kinase in non-small cell lung cancer.

Authors:  Guoan Zhang; Meng Wang; Hongli Zhao; Wen Cui
Journal:  Oncol Lett       Date:  2017-12-27       Impact factor: 2.967

10.  AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.

Authors:  Toni M Brand; Mari Iida; Andrew P Stein; Kelsey L Corrigan; Cara M Braverman; John P Coan; Hannah E Pearson; Harsh Bahrar; Tyler L Fowler; Bryan P Bednarz; Sandeep Saha; David Yang; Parkash S Gill; Mark W Lingen; Vassiliki Saloura; Victoria M Villaflor; Ravi Salgia; Randall J Kimple; Deric L Wheeler
Journal:  Clin Cancer Res       Date:  2015-03-12       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.